IL4 and Nasal polyposis: Dupilumab is an approved therapy for severe asthma, nasal polyposis and atopic dermatitis that inhibits IL-4 and IL-13 signaling by specifically targeting the shared IL-4Rα subunit of their respective receptor complexes40–42.